RBC Capital Maintains Outperform on Repligen, Raises Price Target to $200
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
RBC Capital analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Outperform and raises the price target from $185 to $200.
RBC Capital analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Outperform and raises the price target from $185 to $200.
